These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 25238263)

  • 1. IL-6-stimulated CD11b+ CD14+ HLA-DR- myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus.
    Chen MF; Kuan FC; Yen TC; Lu MS; Lin PY; Chung YH; Chen WC; Lee KD
    Oncotarget; 2014 Sep; 5(18):8716-28. PubMed ID: 25238263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1α,25-Dihydroxyvitamin D3 Inhibits Esophageal Squamous Cell Carcinoma Progression by Reducing IL6 Signaling.
    Chen PT; Hsieh CC; Wu CT; Yen TC; Lin PY; Chen WC; Chen MF
    Mol Cancer Ther; 2015 Jun; 14(6):1365-75. PubMed ID: 25824337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
    Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP
    J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating CD14(+)HLA-DR(-/low) myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC.
    Huang H; Zhang G; Li G; Ma H; Zhang X
    Tumour Biol; 2015 Sep; 36(10):7987-96. PubMed ID: 25967454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD33
    Sun Y; Shao J; Jiang F; Wang Y; Yan Q; Yu N; Zhang J; Zhang J; Li M; He Y
    Am J Reprod Immunol; 2019 Jan; 81(1):e13067. PubMed ID: 30375700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma.
    Zhao Q; Huang L; Qin G; Qiao Y; Ren F; Shen C; Wang S; Liu S; Lian J; Wang D; Yu W; Zhang Y
    Cancer Lett; 2021 Oct; 518():35-48. PubMed ID: 34139285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients.
    Vasquez-Dunddel D; Pan F; Zeng Q; Gorbounov M; Albesiano E; Fu J; Blosser RL; Tam AJ; Bruno T; Zhang H; Pardoll D; Kim Y
    J Clin Invest; 2013 Apr; 123(4):1580-9. PubMed ID: 23454751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
    Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
    J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck.
    Chikamatsu K; Sakakura K; Toyoda M; Takahashi K; Yamamoto T; Masuyama K
    Cancer Sci; 2012 Jun; 103(6):976-83. PubMed ID: 22360618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.
    Zhang B; Wang Z; Wu L; Zhang M; Li W; Ding J; Zhu J; Wei H; Zhao K
    PLoS One; 2013; 8(2):e57114. PubMed ID: 23437326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines.
    Lechner MG; Megiel C; Russell SM; Bingham B; Arger N; Woo T; Epstein AL
    J Transl Med; 2011 Jun; 9():90. PubMed ID: 21658270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating myeloid-derived suppressor cells in patients with pancreatic cancer.
    Xu XD; Hu J; Wang M; Peng F; Tian R; Guo XJ; Xie Y; Qin RY
    Hepatobiliary Pancreat Dis Int; 2016 Feb; 15(1):99-105. PubMed ID: 26818550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.
    Arihara F; Mizukoshi E; Kitahara M; Takata Y; Arai K; Yamashita T; Nakamoto Y; Kaneko S
    Cancer Immunol Immunother; 2013 Aug; 62(8):1421-30. PubMed ID: 23764929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasoactive intestinal peptide induces CD14+HLA-DR‑/low myeloid-derived suppressor cells in gastric cancer.
    Li G; Wu K; Tao K; Lu X; Ma J; Mao Z; Li H; Shi L; Li J; Niu Y; Xiang F; Wang G
    Mol Med Rep; 2015 Jul; 12(1):760-8. PubMed ID: 25695487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion.
    Höchst B; Schildberg FA; Sauerborn P; Gäbel YA; Gevensleben H; Goltz D; Heukamp LC; Türler A; Ballmaier M; Gieseke F; Müller I; Kalff J; Kurts C; Knolle PA; Diehl L
    J Hepatol; 2013 Sep; 59(3):528-35. PubMed ID: 23665041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitric oxide-producing myeloid-derived suppressor cells inhibit vascular E-selectin expression in human squamous cell carcinomas.
    Gehad AE; Lichtman MK; Schmults CD; Teague JE; Calarese AW; Jiang Y; Watanabe R; Clark RA
    J Invest Dermatol; 2012 Nov; 132(11):2642-51. PubMed ID: 22718118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.
    Görgün GT; Whitehill G; Anderson JL; Hideshima T; Maguire C; Laubach J; Raje N; Munshi NC; Richardson PG; Anderson KC
    Blood; 2013 Apr; 121(15):2975-87. PubMed ID: 23321256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer.
    Feng PH; Lee KY; Chang YL; Chan YF; Kuo LW; Lin TY; Chung FT; Kuo CS; Yu CT; Lin SM; Wang CH; Chou CL; Huang CD; Kuo HP
    Am J Respir Crit Care Med; 2012 Nov; 186(10):1025-36. PubMed ID: 22955317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.
    Hoechst B; Ormandy LA; Ballmaier M; Lehner F; Krüger C; Manns MP; Greten TF; Korangy F
    Gastroenterology; 2008 Jul; 135(1):234-43. PubMed ID: 18485901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients.
    Huang A; Zhang B; Wang B; Zhang F; Fan KX; Guo YJ
    Cancer Immunol Immunother; 2013 Sep; 62(9):1439-51. PubMed ID: 23760662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.